PNAS:阻断癌症转移的新策略

2014-01-24 佚名 生物通

血道转移是癌症在体内扩散最常见的方式之一。来自康奈尔大学生物医学工程系的研究人员在一项新研究中提出,血液有可能是阻止癌症转移最理想的位点。这项研究工作发表在近期的《美国科学院院刊》(PNAS)杂志上。 癌细胞从身体的一个部位转移至非相邻位点,会大大降低患者的生存概率——相比于治疗单个位点的肿瘤,针对转移性癌症的治疗往往更具侵袭性,付出的代价也更大。一直以来肿瘤学家们都

血道转移是癌症在体内扩散最常见的方式之一。来自康奈尔大学生物医学工程系的研究人员在一项新研究中提出,血液有可能是阻止癌症转移最理想的位点。这项研究工作发表在近期的《美国科学院院刊》(PNAS)杂志上。【原文下载】

癌细胞从身体的一个部位转移至非相邻位点,会大大降低患者的生存概率——相比于治疗单个位点的肿瘤,针对转移性癌症的治疗往往更具侵袭性,付出的代价也更大。一直以来肿瘤学家们都希望在理想的情况下能够完全地阻断转移。现在,康奈尔大学的研究人员开发出了一项新技术,其或许能够实现这一目标。

在研究白细胞如何通过血流移动的过程中,康奈尔大学生物医学工程学教授Michael King和他的研究小组发现,在炎症位点白细胞借助于一种叫做E-selectin的粘附分子,粘附并在血管壁上移动从而脱离了血液循环。由于相同的粘附分子也是一些癌症转移研究的兴趣靶标,King想知道白细胞和肿瘤细胞运输是否可能利用了相似的机制。

他说:“我们发现癌细胞利用了相同的‘粘附和移动’过程。肿瘤细胞真的劫持了它——这就是肿瘤细胞脱离血液循环,继续改变新的器官或组织的机制。”

当King的研究小组构建出体外系统试图去详细了解这一分子过程时,他想知道破坏这一过程是否能够促使血液循环中的肿瘤细胞死亡。研究表明,一种诱导凋亡的蛋白TRAIL是安全、自然杀死体内肿瘤细胞的一条理想途径。然而针对这一配体进行测试的临床试验并未获得预期的结果。King想到如果采用一种不同的传递系统是否有可能获得更大的效力。于是他和同事们将TRAIL附着到白细胞的表面,然后在体外以及接种前列腺癌或结肠癌的小鼠中进行了测试。

King说:“通过采用这种方法,我们可以让白细胞来完成这一工作。在血流中癌细胞与这些改造的白细胞每发生一次小小的碰撞都有机会导致癌细胞死亡。”

事实上,King对于TRAIL所显示的效力也感到非常的吃惊。他说,在培养皿中治疗癌症都极为的困难,就更不要说像循环系统这样不可预知的环境中。他的研究小组只利用在以往的临床试验中所采用的1/100的TRAIL用量就取得了成功。

King说:“当你将TRAIL倒入到癌细胞培养皿中,它能够很好地发挥作用,杀死大约一半的癌细胞。而当你将它们放置到掺杂有一些癌细胞的循环全血中,你可以彻底地消灭它们。在几个小时之内,这些癌细胞完全土崩瓦解。”

King谨慎地指出,在这项技术能够从基础研究进入到临床应用之前还有大量的工作要做。他计划在更自然的、自发性长期转移模型中测试这项技术。在这样的模型中肿瘤细胞有可能在数周或数月内从原发性位点脱落。他希望这将帮助他的研究小组了解何时应用这种治疗能够取得最大的效益。

原文出处:

Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR.TRAIL-coated leukocytes that kill cancer cells in the circulation.Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):930-5. doi: 10.1073/pnas.1316312111. Epub 2014 Jan 6. 【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1709984, encodeId=e5841e0998454, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri Oct 24 15:20:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855495, encodeId=c12a18554955c, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Feb 13 04:20:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379076, encodeId=d2f413e907680, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Jan 26 00:20:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478340, encodeId=5da014e8340d3, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sun Jan 26 00:20:00 CST 2014, time=2014-01-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1709984, encodeId=e5841e0998454, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri Oct 24 15:20:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855495, encodeId=c12a18554955c, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Feb 13 04:20:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379076, encodeId=d2f413e907680, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Jan 26 00:20:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478340, encodeId=5da014e8340d3, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sun Jan 26 00:20:00 CST 2014, time=2014-01-26, status=1, ipAttribution=)]
    2014-02-13 drwjr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1709984, encodeId=e5841e0998454, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri Oct 24 15:20:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855495, encodeId=c12a18554955c, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Feb 13 04:20:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379076, encodeId=d2f413e907680, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Jan 26 00:20:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478340, encodeId=5da014e8340d3, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sun Jan 26 00:20:00 CST 2014, time=2014-01-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1709984, encodeId=e5841e0998454, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Fri Oct 24 15:20:00 CST 2014, time=2014-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855495, encodeId=c12a18554955c, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Feb 13 04:20:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379076, encodeId=d2f413e907680, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Jan 26 00:20:00 CST 2014, time=2014-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478340, encodeId=5da014e8340d3, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Sun Jan 26 00:20:00 CST 2014, time=2014-01-26, status=1, ipAttribution=)]

相关资讯

Cell:揪出癌症盔甲的薄弱环节

来自约翰霍普金斯大学的细胞生物学家们发现了一种独特的乳腺癌细胞类型,证实其导致了癌症侵袭到周围组织中。由于侵袭是致命的癌症转移过程的第一步,研究人员说他们或许已经找到了癌症盔甲的薄弱环节以及有可能的治疗新靶点。他们的研究结果在线发表在12月12日的《细胞》(Cell)杂志上。 约翰霍普金斯大学医学院细胞生物学助理教授Andrew Ewald博士说:“转移是乳腺癌患者面